The current research paradigm for Huntington's disease is based on participants with overt
clinical phenotypes and does not address its pathophysiology nor the biomarker changes …

Huntington's disease is the most frequent autosomal dominant neurodegenerative disorder;
however, no disease-modifying interventions are available for patients with this disease. The …

Huntington's disease (HD) is a devastating monogenic neurodegenerative disease
characterized by early, selective pathology in the basal ganglia despite the ubiquitous …

Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

In Huntington's disease (HD), striatal projection neurons (SPNs) degenerate during midlife;
the core biological question involves how the disease-causing DNA repeat (CAG) n in the …

Huntington disease (HD) is a fatal progressive neurodegenerative disorder caused by an
inherited mutation in the huntingtin (HTT) gene, which encodes mutant HTT protein. Though …

The longitudinal dynamics of the most promising biofluid biomarker candidates for
Huntington's disease (HD)—mutant huntingtin (mHTT) and neurofilament light (NfL)—are …

Intellectual disability and autism spectrum disorder (ASD) are common, and genetic testing
is increasingly performed in individuals with these diagnoses to inform prognosis, refine …

Huntington's disease (HD) is a neurodegenerative genetic disorder caused by a CAG repeat
expansion in the huntingtin gene. HD causes motor, cognitive, and behavioral dysfunction …

Although the classic symptoms of Huntington's disease (HD) manifest in adulthood, neural
progenitor cell behavior is already abnormal by 13 weeks' gestation. To determine how …